Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: A systematic review and network meta-analysis

Kengkla, 2018, Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis, J Antimicrob Chemother, 73, 22, 10.1093/jac/dkx368

Chuang, 2014, Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis, BMC Infect Dis, 14, 102, 10.1186/1471-2334-14-102

Chopra, 2013, Epidemiology of bloodstream infections caused by Acinetobacter baumannii and impact of drug resistance to both carbapenems and ampicillin-sulbactam on clinical outcomes, Antimicrob Agents Chemother, 57, 6270, 10.1128/AAC.01520-13

Yadav, 2020, Burden of multidrug-resistant acinetobacter baumannii infection in hospitalized patients in a tertiary care hospital of Nepal, Infect Drug Resist, 13, 725, 10.2147/IDR.S239514

Chu, 2013, Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis, Braz J Infect Dis, 17, 389, 10.1016/j.bjid.2012.10.029

Lin, 2015, Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex, Infect Dis (Lond), 47, 370, 10.3109/00365548.2014.995129

Zalts, 2016, Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam, Am J Ther, 23, e78, 10.1097/MJT.0b013e3182a32df3

Katip, 2019, Efficacy and safety of high loading dose of colistin in multidrug-resistant Acinetobacter baumannii: a prospective cohort study, J Intensive Care Med, 34, 996, 10.1177/0885066617725694

Katip, 2017, Clinical outcomes and nephrotoxicity of colistin loading dose for treatment of extensively drug-resistant Acinetobacter baumannii in cancer patients, Infect Drug Resist, 10, 293, 10.2147/IDR.S144314

Alp, 2017, Efficacy of loading dose of colistin in Acinetobacter baumannii ventilator-associated pneumonia, Infez Med, 25, 311

Chusri, 2019, Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii, J Infect Chemother, 25, 681, 10.1016/j.jiac.2019.03.017

Shi, 2019, Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant acinetobacter baumannii pneumonia, Infect Drug Resist, 12, 3925, 10.2147/IDR.S234211

Shi, 2012, [Cefoperazone-sulbactam plus minocycline in the treatment of extensively drug resistant Acinetobacter infections], Zhonghua Yi Xue Za Zhi, 92, 2847

Simsek, 2012, Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?, Indian J Med Microbiol, 30, 448, 10.4103/0255-0857.103767

Javan, 2017, Nephrotoxicity of high and conventional dosing regimens of colistin: a randomized clinical trial, Iran J Pharm Res, 16, 778

Jang, 2017, Efficacy and toxicity of high-dose nebulized colistin for critically ill surgical patients with ventilator-associated pneumonia caused by multidrug-resistant Acinetobacter baumannii, J Crit Care, 40, 251, 10.1016/j.jcrc.2017.04.004

Jung, 2017, Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis, Crit Care, 21, 10.1186/s13054-017-1916-6

Chen, 2017, Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: a systematic review and meta-analysis, J Infect Chemother, 23, 278, 10.1016/j.jiac.2017.01.005

Gkentzi, 2020, Extensively-drug resistant Acinetobacter baumannii bacteremia in neonates: effective treatment with the combination of colistin and ampicillin/sulbactam, J Chemother, 32, 103, 10.1080/1120009X.2020.1716478

Coates, 2020, Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction, Expert Rev Anti Infect Ther, 18, 5, 10.1080/14787210.2020.1705155

Menegucci, 2019, Pharmacodynamic effects of Sulbactam/Meropenem/Polymyxin-B combination against extremely drug resistant Acinetobacter baumannii using checkerboard information, Microb Drug Resist, 25, 1266, 10.1089/mdr.2018.0283

Li, 2019, Efficacy of tigecycline monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii sequence type 2 in Heilongjiang Province, Ann Palliat Med, 8, 651, 10.21037/apm.2019.11.06

Kheshti, 2019, In vitro activity of colistin in combination with various antimicrobials against acinetobacter baumannii species, a report from South Iran, Infect Drug Resist, 12, 129, 10.2147/IDR.S182585

Huang, 2019, Acinetobacter baumannii ventilator-associated pneumonia: clinical efficacy of combined antimicrobial therapy and in vitro drug sensitivity test results, Front Pharmacol, 10

Lenhard, 2017, High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model, Antimicrob Agents Chemother, 61, 10.1128/AAC.01268-16

Mei, 2019, Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis, J Antimicrob Chemother, 74, 3423, 10.1093/jac/dkz337

Dickstein, 2019, Treatment outcomes of colistin- and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial, Clin Infect Dis, 69, 769, 10.1093/cid/ciy988

Vardakas, 2018, Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis, Int J Antimicrob Agents, 51, 535, 10.1016/j.ijantimicag.2017.12.020

Cheng, 2018, Intravenous colistin monotherapy versus combination therapy against carbapenem-resistant gram-negative bacteria infections: meta-analysis of randomized controlled trials, J Clin Med, 7, 10.3390/jcm7080208

Hutton, 2015, The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations, Ann Intern Med, 162, 777, 10.7326/M14-2385

Stang, 2010, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, Eur J Epidemiol, 25, 603, 10.1007/s10654-010-9491-z

Khwaja, 2012, KDIGO clinical practice guidelines for acute kidney injury, Nephron Clin Pract, 120, c179, 10.1159/000339789

DerSimonian, 2015, Meta-analysis in clinical trials revisited, Contemp Clin Trials, 45, 139, 10.1016/j.cct.2015.09.002

Lu, 2004, Combination of direct and indirect evidence in mixed treatment comparisons, Stat Med, 23, 3105, 10.1002/sim.1875

Amat, 2018, The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii, Clin Microbiol Infect, 24, 630, 10.1016/j.cmi.2017.09.016

Aydemir, 2013, Colistin vs. The combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia, Epidemiol Infect, 141, 1214, 10.1017/S095026881200194X

Batirel, 2014, Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections, Eur J Clin Microbiol Infect Dis, 33, 1311, 10.1007/s10096-014-2070-6

Durante-Mangoni, 2013, Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial, Clin Infect Dis, 57, 349, 10.1093/cid/cit253

Garnacho-Montero, 2013, Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii, Chemotherapy, 59, 225, 10.1159/000356004

Kalin, 2014, Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia, Infection, 42, 37, 10.1007/s15010-013-0495-y

Khalili, 2018, Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia, J Comp Eff Res, 7, 901, 10.2217/cer-2018-0037

Khawcharoenporn, 2014, Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia, Int J Antimicrob Agents, 43, 378, 10.1016/j.ijantimicag.2014.01.016

Mosaed, 2018, Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/ sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant acinetobacter, Iran J Pharm Res, 17, 206

Park, 2019, Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem, J Int Med Res, 47, 5977, 10.1177/0300060519879336

Pourheidar, 2019, Comparison of intravenous ampicillin–sulbactam plus nebulized colistin with intravenous colistin plus nebulized colistin in treatment of ventilator associated pneumonia caused by multi drug resistant acinetobacter baumannii: Randomized open label trial, Iran J Pharm Res, 18, 269

Qin, 2015, Tigecycline combined with cefoperazone-sulbactam in treatment of hospital-acquired pneumonia caused by extensively drug resistant Acinetobacter baumannii, Chinese J Infect Chemother, 15, 430

Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13

Wang, 2017, [Efficacy of extended-infusion of carbapenem plus sulbactam for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii], Zhonghua Yi Xue Za Zhi, 97, 2996

Yilmaz, 2015, Colistin alone or combined with sulbactam or carbapenem against A. Baumannii in ventilator-associated pneumonia, J Infect Dev Ctries, 9, 476, 10.3855/jidc.6195

Ungthammakhun, 2019, Clinical outcomes of colistin in combination with either 6-G sulbactam or carbapenems for the treatment of extensively drug-resistant Acinetobacter baumannii pneumonia with high MIC to sulbactam, a prospective cohort study, Infect Drug Resist, 12, 2899, 10.2147/IDR.S225518